Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This phase II study will evaluate and compare the efficacy and tolerability of two dose
schedules (1500 mg QD and 500 mg BID) of oral Lapatinib as treatment for patients with
advanced or metastatic breast cancer.